Vanda Pharmaceuticals (NASDAQ:VNDA) Upgraded by Wall Street Zen to Hold Rating
Wall Street Zen upgraded shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Free Report) from a sell rating to a hold rating in a report issued on Saturday. Other research analysts have also issued research reports about the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $13.00 price objective on shares of Vanda Pharmaceuticals in […]
Wall Street Zen upgraded shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Free Report) from a sell rating to a hold rating in a report issued on Saturday. Other research analysts have also issued research reports about the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $13.00 price objective on shares of Vanda Pharmaceuticals in […]
